ReviewDiscover oncology2025
Alpha 5 integrin as a prognostic biomarker for survival in carcinomas: a systematic review.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Altered integrin expression in carcinomas has been associated with tumor aggressiveness, including survival outcomes. The alpha 5 (α5) integrin is associated with increased proliferation, invasion, migration, and metastasis in various types of cancer, however there is no systematic review on its potential as a prognostic marker for survival outcomes. This systematic review analyzed studies reporting α5 integrin detection by immunohistochemistry and associated survival outcomes, retrieved from PubMed, Embase, Scopus, and the Cochrane Library databases. Fourteen publications met the inclusion criteria including a total of 2,018 patients diagnosed with ovarian, colorectal, liver, cervical, esophageal, pancreatic ductal, tongue or bladder carcinoma. The survival outcomes assessed in these studies included overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and percent survival. Eleven studies reported a positive association between elevated α5 integrin expression and poorer OS or percent survival, while two found no association. Reduced PFS was associated with elevated α5 integrin expression in three studies, whereas two studies reported no such association. One study evaluated α5 integrin expression in relation to RFS and found no association. In conclusion, there is evidence that increased α5 integrin expression is associated with poorer overall and progression-free survival in carcinomas. However, these findings should be further validated through additional research to confirm its potential as a prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.